Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LEROY B VAUGHAN

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1366646697
CMS profile
629902
Location
RICHMOND, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$13,193.85

13 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $13,135.04 11
Ferring Pharmaceuticals Inc. $29.51 1
Melinta Therapeutics, LLC $29.30 1

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LEROY B VAUGHAN

NPI 1366646697 · CMS profile ID 629902

Allopathic & Osteopathic Physicians / Internal Medicine

RICHMOND, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1366646697?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LEROY B VAUGHAN, NPI 1366646697, CMS profile ID 629902. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1366646697?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). LEROY B VAUGHAN, NPI 1366646697, CMS profile ID 629902. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1366646697?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
LEROY B VAUGHAN, NPI 1366646697, CMS profile ID 629902, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1366646697?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

13 matching records · $13,193.85 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 13 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–13 of 13.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $2,875.0012/03/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1204628397 CMS
ABBVIE INC. $124.5911/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204628389 CMS
ABBVIE INC. $7.0011/19/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1204628393 CMS
Ferring Pharmaceuticals Inc. $29.5108/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242088138 CMS
ABBVIE INC. $5.2706/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204628384 CMS
ABBVIE INC. $2,875.0004/25/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1204628381 CMS
ABBVIE INC. $13.9004/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204628377 CMS
ABBVIE INC. $2,875.0003/21/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1204628374 CMS
ABBVIE INC. $123.8203/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204628371 CMS
ABBVIE INC. $4,025.0003/04/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1204628367 CMS
Melinta Therapeutics, LLC $29.3002/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1221035719 CMS
ABBVIE INC. $97.0602/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204628360 CMS
ABBVIE INC. $113.4002/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1204628363 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $59.09 3
PY2022 $20.46 1
PY2023 $6,049.96 8
PY2024 $35,628.74 47
PY2025 $13,193.85 13

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,807,448.32 336
PY2024 Principal investigator $6,183,192.34 199
PY2023 Recipient $1,340.62 4
PY2023 Principal investigator $9,068,826.97 4,189
PY2022 Principal investigator $2,728,925.31 3,261

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

4,193 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novavax Inc $98,061.90 12/27/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1055262099
Principal investigator 1 ModernaTX, Inc. $108,209.03 12/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041205999
Principal investigator 1 ModernaTX, Inc. $188,173.41 12/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041206013
Principal investigator 1 PFIZER INC. $64,716.90 12/22/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046180317
Principal investigator 1 PFIZER INC. $142,013.06 12/21/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046123829
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041202915
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041202943
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041202957
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203001
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203019
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203045
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203061
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203103
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203117
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203131
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203147
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203161
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203177
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203191
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203219
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203233
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203247
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203259
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203287
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203303
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203345
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203375
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203389
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203402
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203447
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203461
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203475
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203575
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203603
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203617
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203631
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203657
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203673
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203731
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203745
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203787
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203829
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203845
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203975
Principal investigator 1 ModernaTX, Inc. $96.60 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203989
Principal investigator 1 ModernaTX, Inc. $300.00 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041205985
Principal investigator 1 ModernaTX, Inc. $109,507.48 12/20/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041206041
Principal investigator 1 ModernaTX, Inc. $75.00 12/18/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041202901
Principal investigator 1 ModernaTX, Inc. $75.00 12/18/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041202971
Principal investigator 1 ModernaTX, Inc. $75.00 12/18/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041202987
Principal investigator 1 ModernaTX, Inc. $75.00 12/18/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203031
Principal investigator 1 ModernaTX, Inc. $75.00 12/18/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203075
Principal investigator 1 ModernaTX, Inc. $75.00 12/18/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203089
Principal investigator 1 ModernaTX, Inc. $75.00 12/18/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203205
Principal investigator 1 ModernaTX, Inc. $75.00 12/18/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203273
Principal investigator 1 ModernaTX, Inc. $75.00 12/18/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203317
Principal investigator 1 ModernaTX, Inc. $75.00 12/18/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203331
Principal investigator 1 ModernaTX, Inc. $75.00 12/18/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203359
Principal investigator 1 ModernaTX, Inc. $75.00 12/18/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203431
Principal investigator 1 ModernaTX, Inc. $75.00 12/18/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203503
Principal investigator 1 ModernaTX, Inc. $75.00 12/18/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203517
Principal investigator 1 ModernaTX, Inc. $75.00 12/18/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203532
Principal investigator 1 ModernaTX, Inc. $75.00 12/18/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203547
Principal investigator 1 ModernaTX, Inc. $75.00 12/18/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203561
Principal investigator 1 ModernaTX, Inc. $75.00 12/18/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203589
Principal investigator 1 ModernaTX, Inc. $75.00 12/18/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203645
Principal investigator 1 ModernaTX, Inc. $75.00 12/18/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203947
Principal investigator 1 ModernaTX, Inc. $75.00 12/18/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203961
Principal investigator 1 ModernaTX, Inc. $75.00 12/15/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041202929
Principal investigator 1 ModernaTX, Inc. $75.00 12/15/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203417
Principal investigator 1 ModernaTX, Inc. $75.00 12/15/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203489
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200015
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041200027
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041200045
Principal investigator 1 ModernaTX, Inc. $1,766.61 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041200119
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200469
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041200483
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041200497
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200511
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200525
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200539
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200553
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200567
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041200579
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041200593
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041200607
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041200623
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041200637
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200653
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041200667
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200681
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041200693
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041200707
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041200743
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201225
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201239
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201253
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201267
Principal investigator 1 ModernaTX, Inc. $1,766.61 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201277
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201291
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201303
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201317
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201331
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201345
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201359
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201375
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201387
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201401
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201415
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201431
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201447
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201463
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201477
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201489
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201505
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201525
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201537
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201553
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201567
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201577
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201591
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201607
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201621
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201633
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201647
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201661
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201675
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201691
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201705
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201719
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201733
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201751
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201765
Principal investigator 1 ModernaTX, Inc. $1,766.61 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201779
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201793
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201807
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201821
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201835
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201849
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201863
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201877
Principal investigator 1 ModernaTX, Inc. $1,766.61 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201893
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201907
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201921
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201937
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201951
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201963
Principal investigator 1 ModernaTX, Inc. $1,766.61 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201977
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041201991
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041202005
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041202019
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041202031
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041202045
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041202063
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041202075
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041202089
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041202103
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041202117
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041202133
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041202147
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041202161
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041202175
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041202189
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041202203
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041202219
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041202235
Principal investigator 1 ModernaTX, Inc. $1,766.61 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041202249
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041202264
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041202277
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041202293
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041202305
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041202319
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041202333
Principal investigator 1 ModernaTX, Inc. $1,766.61 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041202347
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041202361
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041202375
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041202391
Principal investigator 1 ModernaTX, Inc. $1,766.61 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041202405
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041202417
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041202431
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041202445
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041202459
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041202473
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041202487
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041202501
Principal investigator 1 ModernaTX, Inc. $1,766.61 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041202515
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041202529
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041202543
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041202557
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041202569
Principal investigator 1 ModernaTX, Inc. $1,766.61 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041202583
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041202597
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041202611
Principal investigator 1 ModernaTX, Inc. $1,766.61 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041202627
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203687
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203701
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203715
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041203759
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203773
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041203801
Principal investigator 1 ModernaTX, Inc. $1,766.61 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041203815
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041203857
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041203873
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041203885
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041203901
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203919
Principal investigator 1 ModernaTX, Inc. $739.68 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041203933
Principal investigator 1 ModernaTX, Inc. $2,262.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041204007
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041204021
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041204035
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041204057
Principal investigator 1 ModernaTX, Inc. $2,424.87 12/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041204067
Principal investigator 1 PFIZER INC. $8,974.80 12/14/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046177191
Principal investigator 1 ModernaTX, Inc. $45.00 12/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200105
Principal investigator 1 ModernaTX, Inc. $4,000.00 12/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200351
Principal investigator 1 ModernaTX, Inc. $45.00 12/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200719
Principal investigator 1 ModernaTX, Inc. $45.00 12/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200731
Principal investigator 1 ModernaTX, Inc. $45.00 12/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200757
Principal investigator 1 ModernaTX, Inc. $45.00 12/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200823
Principal investigator 1 ModernaTX, Inc. $45.00 12/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200865
Principal investigator 1 ModernaTX, Inc. $45.00 12/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200877
Principal investigator 1 ModernaTX, Inc. $45.00 12/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200909
Principal investigator 1 ModernaTX, Inc. $45.00 12/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201007
Principal investigator 1 ModernaTX, Inc. $45.00 12/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201021
Principal investigator 1 ModernaTX, Inc. $45.00 12/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201035
Principal investigator 1 ModernaTX, Inc. $45.00 12/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201079
Principal investigator 1 ModernaTX, Inc. $45.00 12/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201123
Principal investigator 1 ModernaTX, Inc. $45.00 12/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201167
Principal investigator 1 ModernaTX, Inc. $45.00 12/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201209
Principal investigator 1 PFIZER INC. $587.00 12/11/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046038249
Principal investigator 1 PFIZER INC. $37.60 12/09/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045964317
Principal investigator 1 ModernaTX, Inc. $6,568.80 12/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200091
Principal investigator 1 ModernaTX, Inc. $16,953.30 12/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200189
Principal investigator 1 ModernaTX, Inc. $6,472.20 12/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200321
Principal investigator 1 ModernaTX, Inc. $8,694.00 12/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200337
Principal investigator 1 ModernaTX, Inc. $5,796.00 12/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200395
Principal investigator 1 ModernaTX, Inc. $8,114.40 12/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200425
Principal investigator 1 ModernaTX, Inc. $16,953.30 12/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201195
Principal investigator 1 PFIZER INC. $53,634.24 12/07/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046170675
Principal investigator 1 ModernaTX, Inc. $345.00 12/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200077
Principal investigator 1 ModernaTX, Inc. $73.14 12/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200147
Principal investigator 1 ModernaTX, Inc. $262.20 12/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200175
Principal investigator 1 ModernaTX, Inc. $255.30 12/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200217
Principal investigator 1 ModernaTX, Inc. $69.00 12/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200231
Principal investigator 1 ModernaTX, Inc. $4,636.80 12/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200247
Principal investigator 1 ModernaTX, Inc. $213.90 12/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200307
Principal investigator 1 ModernaTX, Inc. $186.30 12/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200411
Principal investigator 1 ModernaTX, Inc. $255.30 12/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200771
Principal investigator 1 ModernaTX, Inc. $262.20 12/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200785
Principal investigator 1 ModernaTX, Inc. $345.00 12/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200795
Principal investigator 1 ModernaTX, Inc. $4,636.80 12/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200809
Principal investigator 1 ModernaTX, Inc. $262.20 12/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200851
Principal investigator 1 ModernaTX, Inc. $69.00 12/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200891
Principal investigator 1 ModernaTX, Inc. $73.14 12/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200923
Principal investigator 1 ModernaTX, Inc. $69.00 12/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200937
Principal investigator 1 ModernaTX, Inc. $255.30 12/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200951
Principal investigator 1 ModernaTX, Inc. $213.90 12/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200965
Principal investigator 1 ModernaTX, Inc. $345.00 12/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200993
Principal investigator 1 ModernaTX, Inc. $255.30 12/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201049
Principal investigator 1 ModernaTX, Inc. $345.00 12/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201065
Principal investigator 1 ModernaTX, Inc. $69.00 12/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201107
Principal investigator 1 ModernaTX, Inc. $69.00 12/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201137
Principal investigator 1 ModernaTX, Inc. $262.20 12/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201153
Principal investigator 1 ModernaTX, Inc. $69.00 12/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201181
Principal investigator 1 ModernaTX, Inc. $6,665.40 12/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200161
Principal investigator 1 ModernaTX, Inc. $1,615.98 12/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200263
Principal investigator 1 ModernaTX, Inc. $5,409.60 12/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200275
Principal investigator 1 ModernaTX, Inc. $8,887.20 12/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200293
Principal investigator 1 ModernaTX, Inc. $15,745.80 12/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200365
Principal investigator 1 ModernaTX, Inc. $25,405.80 12/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200379
Principal investigator 1 ModernaTX, Inc. $9,370.20 12/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200439
Principal investigator 1 ModernaTX, Inc. $24,246.60 12/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200453
Principal investigator 1 ModernaTX, Inc. $4,000.00 12/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041206027
Principal investigator 1 PFIZER INC. $403.92 12/04/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046229144
Principal investigator 1 ModernaTX, Inc. $13,379.10 12/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200001
Principal investigator 1 ModernaTX, Inc. $13,712.20 12/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200061
Principal investigator 1 ModernaTX, Inc. $16,905.00 12/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200133
Principal investigator 1 ModernaTX, Inc. $4,347.00 12/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200203
Principal investigator 1 ModernaTX, Inc. $13,379.10 12/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200839
Principal investigator 1 ModernaTX, Inc. $16,905.00 12/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041200979
Principal investigator 1 ModernaTX, Inc. $13,712.20 12/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041201093
Principal investigator 1 Novavax Inc $170,530.28 11/29/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1055259131
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197307
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197321
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041197337
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041197349
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041197365
Principal investigator 1 ModernaTX, Inc. $1,766.61 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041197381
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041197395
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041197411
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041197425
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197439
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197453
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197467
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197481
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197495
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197507
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197519
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197533
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197547
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197561
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197575
Principal investigator 1 ModernaTX, Inc. $1,766.61 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041197589
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041197603
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041197617
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041197631
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041197645
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197659
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197674
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197687
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197701
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197715
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041197745
Principal investigator 1 ModernaTX, Inc. $1,766.61 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041197759
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041197773
Principal investigator 1 ModernaTX, Inc. $2,053.62 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041197789
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197817
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197831
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197847
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041197861
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041197877
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197889
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197903
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197917
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197931
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197945
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041197959
Principal investigator 1 ModernaTX, Inc. $1,766.61 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041197973
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041197987
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041198001
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041198015
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041198029
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198043
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198057
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198071
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198085
Principal investigator 1 ModernaTX, Inc. $1,078.33 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198099
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198113
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198127
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198141
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198155
Principal investigator 1 ModernaTX, Inc. $1,766.61 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041198167
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041198183
Principal investigator 1 ModernaTX, Inc. $1,766.61 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041198197
Principal investigator 1 ModernaTX, Inc. $1,766.61 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041198209
Principal investigator 1 ModernaTX, Inc. $1,766.61 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041198223
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041198237
Principal investigator 1 ModernaTX, Inc. $1,766.61 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041198251
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198265
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198281
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198295
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198309
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198351
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198365
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198379
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198393
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198407
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198421
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198435
Principal investigator 1 ModernaTX, Inc. $1,766.61 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041198449
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198463
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198473
Principal investigator 1 ModernaTX, Inc. $1,078.33 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198483
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198497
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198513
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041198527
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041198541
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041198555
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041198569
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041198583
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041198597
Principal investigator 1 ModernaTX, Inc. $1,766.61 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041198611
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041198625
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198639
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198651
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198667
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198681
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198695
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198711
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198725
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041198739
Principal investigator 1 ModernaTX, Inc. $1,766.61 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041198753
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198767
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198781
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198797
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198811
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198825
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198841
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198857
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041198871
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041198897
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041198911
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041198925
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198939
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198955
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198969
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198983
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198997
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199011
Principal investigator 1 ModernaTX, Inc. $2,053.62 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199027
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199041
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199055
Principal investigator 1 ModernaTX, Inc. $1,766.61 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199069
Principal investigator 1 ModernaTX, Inc. $1,766.61 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199081
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199097
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199113
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199127
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199141
Principal investigator 1 ModernaTX, Inc. $1,766.61 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199157
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199171
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199185
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199199
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199219
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199233
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199247
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199263
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199275
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199289
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199305
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199317
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199331
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199348
Principal investigator 1 ModernaTX, Inc. $1,766.61 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199363
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199377
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199391
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199405
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199421
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199433
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199447
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199461
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199475
Principal investigator 1 ModernaTX, Inc. $1,766.61 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199489
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199503
Principal investigator 1 ModernaTX, Inc. $2,262.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199517
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199531
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199545
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199559
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199575
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199591
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199605
Principal investigator 1 ModernaTX, Inc. $1,766.61 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199619
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199633
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199651
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199667
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199683
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199697
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199711
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199725
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199739
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199755
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199769
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199785
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199799
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199811
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199827
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199841
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199855
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199869
Principal investigator 1 ModernaTX, Inc. $1,766.61 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199883
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199897
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199911
Principal investigator 1 ModernaTX, Inc. $1,766.61 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199927
Principal investigator 1 ModernaTX, Inc. $2,424.87 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041199941
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199957
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199971
Principal investigator 1 ModernaTX, Inc. $739.68 11/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041199987
Principal investigator 1 PFIZER INC. $42,411.28 11/25/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046022157
Principal investigator 1 ModernaTX, Inc. $91,343.41 11/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041205901
Principal investigator 1 ModernaTX, Inc. $840.05 11/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041197731
Principal investigator 1 ModernaTX, Inc. $34,099.80 11/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197803
Principal investigator 1 ModernaTX, Inc. $33,713.40 11/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198337
Principal investigator 1 Novavax Inc $15,631.50 11/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1055259129
Principal investigator 1 ModernaTX, Inc. $67,330.20 11/03/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041198323
Principal investigator 1 PFIZER INC. $61,776.10 11/03/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046152591
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194031
Principal investigator 1 ModernaTX, Inc. $1,078.33 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194049
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194063
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194079
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194093
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194105
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194119
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194133
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194149
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194163
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194177
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194193
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194207
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194221
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194235
Principal investigator 1 ModernaTX, Inc. $1,078.33 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194249
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194265
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194279
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194297
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194311
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194327
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194339
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194355
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194369
Principal investigator 1 ModernaTX, Inc. $1,078.33 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194383
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194399
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194413
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194427
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194443
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194457
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194471
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194487
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194499
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194515
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194531
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194543
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194557
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194571
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194589
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194602
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194615
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194629
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194643
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194657
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194675
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194689
Principal investigator 1 ModernaTX, Inc. $1,078.33 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194701
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194715
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194731
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194745
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194761
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194777
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194791
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194805
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194819
Principal investigator 1 ModernaTX, Inc. $1,078.33 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194835
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194849
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194865
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194879
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194893
Principal investigator 1 ModernaTX, Inc. $1,078.33 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194909
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194925
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194941
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194957
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194971
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194983
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041194999
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195013
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195031
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195043
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195055
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195069
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195083
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195097
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195111
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195127
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195143
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195157
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195171
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195183
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195195
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195209
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195229
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195241
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195255
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195269
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195283
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195299
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195313
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195487
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195499
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195515
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195533
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195547
Principal investigator 1 ModernaTX, Inc. $1,078.33 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195561
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195573
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195589
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195601
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195619
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195635
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195649
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195663
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195677
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195693
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195705
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195721
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195735
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195749
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195763
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195777
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195791
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195807
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195821
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195835
Principal investigator 1 ModernaTX, Inc. $1,078.33 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195849
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195861
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195875
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195889
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195905
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195919
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195933
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195949
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195963
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195977
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041195991
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196005
Principal investigator 1 ModernaTX, Inc. $1,078.33 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196019
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196037
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196053
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196067
Principal investigator 1 ModernaTX, Inc. $1,078.33 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196081
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196095
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196111
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196125
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196140
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196155
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196169
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196183
Principal investigator 1 ModernaTX, Inc. $1,078.33 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196195
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196207
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196227
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196241
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196255
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196269
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196283
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196297
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196311
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196327
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196341
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196355
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196371
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196383
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196395
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196409
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196421
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196439
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196453
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196469
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196483
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196499
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196513
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196527
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196539
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196557
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196575
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196591
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196605
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196619
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196635
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196649
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196661
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196675
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196691
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196707
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196721
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196735
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196749
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196763
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196779
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196795
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196809
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196824
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196839
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196849
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196865
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196877
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196891
Principal investigator 1 ModernaTX, Inc. $1,078.33 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196905
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196919
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196933
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196947
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196963
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196977
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041196989
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197005
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197019
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197031
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197047
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197061
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197077
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197093
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197107
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197121
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197135
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197149
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197163
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197179
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197191
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197205
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197219
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197233
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197249
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197263
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197277
Principal investigator 1 ModernaTX, Inc. $739.68 10/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041197293
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191137
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191151
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191171
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191185
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191215
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191229
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191245
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191275
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191289
Principal investigator 1 ModernaTX, Inc. $1,766.61 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191307
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191321
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192607
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192623
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192635
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192651
Principal investigator 1 ModernaTX, Inc. $1,766.61 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192665
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192677
Principal investigator 1 ModernaTX, Inc. $275.00 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192689
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192705
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192721
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192735
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192749
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192763
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192779
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192793
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192807
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192821
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192835
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192849
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192861
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192875
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192885
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192901
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192915
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192929
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192943
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192957
Principal investigator 1 ModernaTX, Inc. $3,100.00 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192971
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192987
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193001
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193015
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193029
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193043
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193055
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193069
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193083
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193097
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193111
Principal investigator 1 ModernaTX, Inc. $1,766.61 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193123
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193139
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193153
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193167
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193181
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193197
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193213
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193227
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193239
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193255
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193267
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193285
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193299
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193313
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193329
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193343
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193357
Principal investigator 1 ModernaTX, Inc. $1,766.61 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193371
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193385
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193401
Principal investigator 1 ModernaTX, Inc. $1,766.61 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193417
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193431
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193443
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193459
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193473
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193489
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193505
Principal investigator 1 ModernaTX, Inc. $1,766.61 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193519
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193533
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193547
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193561
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193577
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193589
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193605
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193617
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193631
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193647
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193661
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193675
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193691
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193703
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193717
Principal investigator 1 ModernaTX, Inc. $1,766.61 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193741
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193755
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193767
Principal investigator 1 ModernaTX, Inc. $801.90 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193781
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193791
Principal investigator 1 ModernaTX, Inc. $1,766.61 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193805
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193819
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193833
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193849
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193861
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193877
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193891
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193905
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193921
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193935
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193949
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193961
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193975
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041193991
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041194007
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041194021
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041195325
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041195339
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041195355
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041195369
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041195385
Principal investigator 1 ModernaTX, Inc. $700.65 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041195399
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041195411
Principal investigator 1 ModernaTX, Inc. $1,766.61 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041195425
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041195443
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041195459
Principal investigator 1 ModernaTX, Inc. $2,053.62 10/26/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041195471
Principal investigator 1 PFIZER INC. $105,492.50 10/24/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046157551
Principal investigator 1 PFIZER INC. $20,929.34 10/18/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046157851
Principal investigator 1 PFIZER INC. $2,300.00 10/14/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046304661
Principal investigator 1 PFIZER INC. $50,124.20 10/12/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046203205
Principal investigator 1 ModernaTX, Inc. $401.03 10/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041191199
Principal investigator 1 ModernaTX, Inc. $739.68 10/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041191259
Principal investigator 1 ModernaTX, Inc. $401.03 10/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041191335
Principal investigator 1 ModernaTX, Inc. $401.03 10/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041191347
Principal investigator 1 ModernaTX, Inc. $401.03 10/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041191361
Principal investigator 1 ModernaTX, Inc. $401.03 10/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041191375
Principal investigator 1 ModernaTX, Inc. $401.03 10/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041191391
Principal investigator 1 ModernaTX, Inc. $401.03 10/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041191405
Principal investigator 1 ModernaTX, Inc. $401.03 10/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041191419
Principal investigator 1 ModernaTX, Inc. $401.03 10/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041191433
Principal investigator 1 ModernaTX, Inc. $739.68 10/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041191447
Principal investigator 1 ModernaTX, Inc. $739.68 10/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041191461
Principal investigator 1 ModernaTX, Inc. $401.03 10/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041191475
Principal investigator 1 ModernaTX, Inc. $401.03 10/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041191491
Principal investigator 1 ModernaTX, Inc. $739.68 10/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041191505
Principal investigator 1 ModernaTX, Inc. $739.68 10/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041191519
Principal investigator 1 ModernaTX, Inc. $401.03 10/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041191537
Principal investigator 1 ModernaTX, Inc. $806.27 10/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041191757
Principal investigator 1 ModernaTX, Inc. $401.03 10/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041191773
Principal investigator 1 ModernaTX, Inc. $401.03 10/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041191801
Principal investigator 1 ModernaTX, Inc. $401.03 10/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041191955
Principal investigator 1 ModernaTX, Inc. $739.68 10/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041192097
Principal investigator 1 ModernaTX, Inc. $401.03 10/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041192109
Principal investigator 1 ModernaTX, Inc. $401.03 10/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041192351
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187173
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187189
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187203
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187217
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187231
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187249
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187263
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187291
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187301
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187315
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187331
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187345
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187361
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187371
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187385
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187399
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187413
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187427
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187441
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187457
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187471
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187483
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187497
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187509
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187519
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187529
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187543
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187557
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187569
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187579
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187593
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187613
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187625
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187637
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187653
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187667
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187683
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187699
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187711
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187725
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187739
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187755
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187769
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187783
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187797
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187815
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187829
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187843
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187859
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187871
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187887
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187901
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187933
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187947
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187961
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187975
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187989
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188003
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188017
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188035
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188051
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188063
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188079
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188097
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188111
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188125
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188139
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188153
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188241
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188251
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188269
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188283
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188297
Principal investigator 1 ModernaTX, Inc. $700.65 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188313
Principal investigator 1 ModernaTX, Inc. $1,766.61 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188327
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188343
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188357
Principal investigator 1 ModernaTX, Inc. $1,766.61 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188371
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188385
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188401
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188415
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188428
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188443
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188455
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188471
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188487
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188501
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188515
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188529
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188551
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188567
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188581
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188594
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188609
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188623
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188639
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188653
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188667
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188681
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188695
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188709
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188725
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188741
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188755
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188767
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188781
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188799
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188813
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188827
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188841
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188855
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188869
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188883
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188899
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188913
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188927
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188939
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188953
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188969
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188981
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188995
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189011
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189025
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189039
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189055
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189067
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189086
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189095
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189109
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189123
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189139
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189153
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189167
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189181
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189195
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189209
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189223
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189239
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189253
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189267
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189281
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189295
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189309
Principal investigator 1 ModernaTX, Inc. $700.65 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189323
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189339
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189353
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189367
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189381
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189395
Principal investigator 1 ModernaTX, Inc. $1,766.61 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189409
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189423
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189437
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189455
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189469
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189483
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189497
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189511
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189523
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189536
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189551
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189565
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189579
Principal investigator 1 ModernaTX, Inc. $1,766.61 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189591
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189607
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189621
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189639
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189653
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189667
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189687
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189697
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189711
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189729
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189741
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189757
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189771
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189785
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189803
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189817
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189831
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189843
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189858
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189873
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189891
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189905
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189919
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189933
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189947
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189961
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189975
Principal investigator 1 ModernaTX, Inc. $1,766.61 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041189989
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190001
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190017
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190033
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190048
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190061
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190075
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190091
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190107
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190121
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190135
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190151
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190165
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190179
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190193
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190207
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190221
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190235
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190249
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190263
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190277
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190291
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190305
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190319
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190335
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190353
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190367
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190381
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190393
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190407
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190421
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190437
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190450
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190465
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190481
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190495
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190511
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190525
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190541
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190553
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190571
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190585
Principal investigator 1 ModernaTX, Inc. $1,766.61 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190601
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190615
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190629
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190645
Principal investigator 1 ModernaTX, Inc. $700.65 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190657
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190673
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190689
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190703
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190719
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190733
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190749
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190763
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190779
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190793
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190807
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190821
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190835
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190849
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190863
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190877
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190889
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190903
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190919
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190935
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190947
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190961
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190975
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041190989
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191005
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191017
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191035
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191053
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191067
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191081
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191095
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191109
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191123
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191551
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191567
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191583
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191597
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191613
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191629
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191643
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191657
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191671
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191685
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191699
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191713
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191727
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191743
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191787
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191817
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191829
Principal investigator 1 ModernaTX, Inc. $700.65 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191845
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191859
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191873
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191887
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191902
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191915
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191929
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191943
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191975
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041191991
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192007
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192021
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192037
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192053
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192067
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192081
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192123
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192139
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192151
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192171
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192187
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192203
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192219
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192233
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192247
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192261
Principal investigator 1 ModernaTX, Inc. $700.65 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192277
Principal investigator 1 ModernaTX, Inc. $1,766.61 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192292
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192307
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192321
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192335
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192363
Principal investigator 1 ModernaTX, Inc. $700.65 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192381
Principal investigator 1 ModernaTX, Inc. $801.90 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192397
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192409
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192423
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192437
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192450
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192463
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192479
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192491
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192505
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192519
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192533
Principal investigator 1 ModernaTX, Inc. $4,745.93 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192547
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192564
Principal investigator 1 ModernaTX, Inc. $20.25 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192577
Principal investigator 1 ModernaTX, Inc. $2,262.87 10/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041192593
Principal investigator 1 PFIZER INC. $300.00 10/03/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046126197
Principal investigator 1 ModernaTX, Inc. $500.00 10/02/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187281
Principal investigator 1 ModernaTX, Inc. $34,776.00 10/02/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041187601
Principal investigator 1 ModernaTX, Inc. $34,003.20 10/02/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041187919
Principal investigator 1 ModernaTX, Inc. $37,191.00 10/02/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041188167
Principal investigator 1 ModernaTX, Inc. $5,000.00 10/02/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188181
Principal investigator 1 ModernaTX, Inc. $30,332.40 10/02/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041188195
Principal investigator 1 ModernaTX, Inc. $1,300.00 10/02/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041188209
Principal investigator 1 ModernaTX, Inc. $33,713.40 10/02/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041188223
Principal investigator 1 Novavax Inc $8,500.00 09/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1055259127
Principal investigator 1 Novavax Inc $3,500.00 09/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1055266045
Principal investigator 1 Novavax Inc $5,000.00 09/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1055266047
Principal investigator 1 PFIZER INC. $267.72 09/15/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045973903
Principal investigator 1 PFIZER INC. $98,263.24 09/14/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1045978593
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041183937
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041183951
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183967
Principal investigator 1 ModernaTX, Inc. $700.65 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183981
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183997
Principal investigator 1 ModernaTX, Inc. $20.25 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184013
Principal investigator 1 ModernaTX, Inc. $700.65 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184027
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184041
Principal investigator 1 ModernaTX, Inc. $1,766.61 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184055
Principal investigator 1 ModernaTX, Inc. $1,766.61 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184069
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041184085
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041184101
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184115
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184129
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184143
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041184157
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041184171
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041184185
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041184199
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041184213
Principal investigator 1 ModernaTX, Inc. $700.65 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184225
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184239
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184253
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184267
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041184283
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041184297
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041184311
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041184329
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041184343
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041184359
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184399
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184413
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184427
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184441
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184455
Principal investigator 1 ModernaTX, Inc. $1,766.61 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184469
Principal investigator 1 ModernaTX, Inc. $20.25 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184483
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184497
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184511
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041184525
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041184539
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041184557
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041184573
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184607
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184619
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184635
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184649
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184661
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184675
Principal investigator 1 ModernaTX, Inc. $1,766.61 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184689
Principal investigator 1 ModernaTX, Inc. $700.65 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184705
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184717
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184731
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184745
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184759
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184773
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041184789
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041184805
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041184819
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041184831
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041184847
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184874
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184887
Principal investigator 1 ModernaTX, Inc. $700.65 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184903
Principal investigator 1 ModernaTX, Inc. $801.90 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184917
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184931
Principal investigator 1 ModernaTX, Inc. $801.90 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184947
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184965
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041184979
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184993
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185006
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185021
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185035
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185049
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185063
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185079
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185091
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185103
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041185117
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185131
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185145
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185159
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185173
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185185
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041185199
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041185213
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041185371
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041185385
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185399
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185413
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185427
Principal investigator 1 ModernaTX, Inc. $700.65 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185441
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185455
Principal investigator 1 ModernaTX, Inc. $1,766.61 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185469
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185483
Principal investigator 1 ModernaTX, Inc. $1,766.61 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185497
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041185511
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041185525
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041185541
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041185557
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185573
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185587
Principal investigator 1 ModernaTX, Inc. $700.65 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185601
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185615
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185629
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185643
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185657
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185671
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041185686
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041185701
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185715
Principal investigator 1 ModernaTX, Inc. $20.25 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185731
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185743
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185759
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185771
Principal investigator 1 ModernaTX, Inc. $4,745.93 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185787
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185801
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185815
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185831
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185845
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041185859
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041185873
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041185889
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041185903
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185917
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185931
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185945
Principal investigator 1 ModernaTX, Inc. $20.25 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185961
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185977
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185989
Principal investigator 1 ModernaTX, Inc. $1,766.61 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186003
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186017
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186029
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186043
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186057
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041186071
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186087
Principal investigator 1 ModernaTX, Inc. $4,745.93 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186097
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186111
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186125
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186137
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186153
Principal investigator 1 ModernaTX, Inc. $4,745.93 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186169
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186183
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186199
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186219
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186233
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186247
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041186263
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041186278
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041186291
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041186307
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041186321
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041186335
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186347
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186362
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186377
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186391
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186405
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186421
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186435
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186451
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041186463
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041186477
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041186495
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041186511
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041186531
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186545
Principal investigator 1 ModernaTX, Inc. $700.65 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186559
Principal investigator 1 ModernaTX, Inc. $1,766.61 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186573
Principal investigator 1 ModernaTX, Inc. $20.25 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186589
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186603
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186619
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186629
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186645
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186659
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186673
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186689
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041186705
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041186719
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041186733
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041186747
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041186761
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041186777
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041186791
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041186805
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041186821
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041186835
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041186851
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041186865
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041186879
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186895
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041186911
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041186925
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041186939
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186953
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186967
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186981
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041186995
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187013
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187027
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187041
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187055
Principal investigator 1 ModernaTX, Inc. $1,766.61 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187069
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187083
Principal investigator 1 ModernaTX, Inc. $2,262.87 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187097
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041187115
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041187131
Principal investigator 1 ModernaTX, Inc. $739.68 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041187141
Principal investigator 1 ModernaTX, Inc. $2,053.62 09/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041187157
Principal investigator 1 ModernaTX, Inc. $45.00 09/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041185329
Principal investigator 1 PFIZER INC. $403.92 09/05/2023 Non-covered Recipient Entity
Clinical Research Partners
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046258305
Principal investigator 1 ModernaTX, Inc. $94.50 09/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183895
Principal investigator 1 ModernaTX, Inc. $45.90 09/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183909
Principal investigator 1 ModernaTX, Inc. $45.90 09/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183923
Principal investigator 1 ModernaTX, Inc. $94.50 09/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184373
Principal investigator 1 ModernaTX, Inc. $6,900.00 09/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184385
Principal investigator 1 ModernaTX, Inc. $45.90 09/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184593
Principal investigator 1 ModernaTX, Inc. $45.90 09/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041184859
Principal investigator 1 ModernaTX, Inc. $94.50 09/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185231
Principal investigator 1 ModernaTX, Inc. $94.50 09/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185243
Principal investigator 1 ModernaTX, Inc. $500.00 09/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185257
Principal investigator 1 ModernaTX, Inc. $94.50 09/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185273
Principal investigator 1 ModernaTX, Inc. $45.90 09/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185287
Principal investigator 1 ModernaTX, Inc. $45.90 09/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185301
Principal investigator 1 ModernaTX, Inc. $94.50 09/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185315
Principal investigator 1 ModernaTX, Inc. $94.50 09/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185343
Principal investigator 1 ModernaTX, Inc. $45.90 09/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041185357
Principal investigator 1 ModernaTX, Inc. $45.00 08/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041183881
Principal investigator 1 PFIZER INC. $41,971.44 08/25/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046083905
Principal investigator 1 PFIZER INC. $116,774.63 08/24/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1045990601
Principal investigator 1 ModernaTX, Inc. $101.25 08/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183615
Principal investigator 1 ModernaTX, Inc. $303.75 08/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183639
Principal investigator 1 ModernaTX, Inc. $500.00 08/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183671
Principal investigator 1 ModernaTX, Inc. $337.50 08/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183757
Principal investigator 1 ModernaTX, Inc. $243.00 08/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183769
Principal investigator 1 ModernaTX, Inc. $94.50 08/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183811
Principal investigator 1 ModernaTX, Inc. $67.50 08/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183825
Principal investigator 1 ModernaTX, Inc. $93.96 08/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183839
Principal investigator 1 ModernaTX, Inc. $106.65 08/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183853
Principal investigator 1 PFIZER INC. $3,062.07 08/22/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046104527
Principal investigator 1 ModernaTX, Inc. $500.00 08/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183657
Principal investigator 1 PFIZER INC. $12,713.93 08/17/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045926631
Principal investigator 1 ModernaTX, Inc. $87.75 08/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183685
Principal investigator 1 ModernaTX, Inc. $87.75 08/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183701
Principal investigator 1 ModernaTX, Inc. $87.75 08/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183741
Principal investigator 1 ModernaTX, Inc. $87.75 08/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183783
Principal investigator 1 ModernaTX, Inc. $87.75 08/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183797
Principal investigator 1 ModernaTX, Inc. $87.75 08/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183867
Principal investigator 1 ModernaTX, Inc. $40.00 08/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041207017
Principal investigator 1 ModernaTX, Inc. $33,810.00 08/11/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041183627
Principal investigator 1 ModernaTX, Inc. $34,003.20 08/11/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041183727
Principal investigator 1 PFIZER INC. $15,439.44 08/09/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046261307
Principal investigator 1 ModernaTX, Inc. $33,906.60 08/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041183715
Recipient Novavax Inc $801.05 08/04/2023 Covered Recipient Physician A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1055258571
Recipient Novavax Inc $190.97 08/04/2023 Covered Recipient Physician A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1055258697
Recipient Novavax Inc $166.57 08/04/2023 Covered Recipient Physician A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1055258737
Recipient Novavax Inc $182.03 08/04/2023 Covered Recipient Physician A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1055258739
Principal investigator 1 PFIZER INC. $3,617.25 07/26/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046112497
Principal investigator 1 PFIZER INC. $106,237.36 07/25/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046324041
Principal investigator 1 ModernaTX, Inc. $600.00 07/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041205873
Principal investigator 1 ModernaTX, Inc. $900.00 07/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041205885
Principal investigator 1 PFIZER INC. $80,550.87 07/08/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046235973
Principal investigator 1 PFIZER INC. $4,623.00 07/06/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045994485
Principal investigator 1 ModernaTX, Inc. $19,609.80 06/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041182521
Principal investigator 1 ModernaTX, Inc. $19,899.60 06/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041182535
Principal investigator 1 ModernaTX, Inc. $333.00 06/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041784249
Principal investigator 1 PFIZER INC. $10,830.75 06/29/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046327093
Principal investigator 1 ModernaTX, Inc. $8,500.00 06/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041205831
Principal investigator 1 ModernaTX, Inc. $300.00 06/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041205859
Principal investigator 1 ModernaTX, Inc. $120.00 06/28/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041207003
Principal investigator 1 PFIZER INC. $294,081.44 06/24/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046332133
Principal investigator 1 PFIZER INC. $46,321.23 06/22/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046330121
Principal investigator 1 ModernaTX, Inc. $150.00 06/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041182549
Principal investigator 1 PFIZER INC. $65,663.85 06/16/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046123813
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172503
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172517
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172529
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172543
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172557
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172573
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172581
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172595
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172609
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172619
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172629
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172647
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172663
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172677
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172691
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172705
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172719
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172733
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172747
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172761
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172775
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172789
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172803
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172819
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172833
Principal investigator 1 ModernaTX, Inc. $3,148.47 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172847
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172861
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172875
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172893
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172905
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172920
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041173939
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041173953
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041173967
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041173981
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041173995
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174009
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174025
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174039
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174053
Principal investigator 1 ModernaTX, Inc. $3,148.47 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174067
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174083
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174097
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174113
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174127
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174141
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174155
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174169
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174183
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174197
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174211
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174225
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174239
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174253
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174271
Principal investigator 1 ModernaTX, Inc. $3,148.47 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174285
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174299
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174313
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174329
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174343
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174361
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174371
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174387
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174401
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174415
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174431
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174447
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174461
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174475
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174489
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174503
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174517
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174531
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174545
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174559
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174573
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174591
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174605
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174619
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174633
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174647
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174661
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174675
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174691
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174705
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174717
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174733
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174749
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174763
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174777
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174791
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174805
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174823
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174839
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174853
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174867
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174881
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174893
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174909
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174923
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174937
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174951
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174965
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174979
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041174997
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175011
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175025
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175039
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175053
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175067
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175081
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175099
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175113
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175127
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175141
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175155
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175169
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175183
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175197
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175213
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175227
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175241
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175255
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175271
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175285
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175299
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175311
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175325
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175339
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175353
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175371
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175382
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175399
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175411
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175425
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175443
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175459
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175473
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175487
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175501
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175515
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175529
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175543
Principal investigator 1 ModernaTX, Inc. $3,148.47 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175559
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175573
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175587
Principal investigator 1 ModernaTX, Inc. $3,148.47 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175601
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175615
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175631
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175645
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175659
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175673
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175689
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175709
Principal investigator 1 ModernaTX, Inc. $3,148.47 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175723
Principal investigator 1 ModernaTX, Inc. $3,148.47 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175739
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175753
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175769
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175783
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175797
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175811
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175825
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175839
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175853
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175869
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175883
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175898
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175913
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175927
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175943
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175957
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175971
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175985
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041175999
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176013
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176031
Principal investigator 1 ModernaTX, Inc. $3,148.47 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176047
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176061
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176073
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176087
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176097
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176113
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176129
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176143
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176157
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176171
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176185
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176199
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176213
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176229
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176245
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176257
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176271
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176285
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176303
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176319
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176335
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176349
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176365
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176381
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176397
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176411
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176425
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176439
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176453
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176467
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176481
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176497
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176507
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176525
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176541
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176553
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176567
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176583
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176597
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176611
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176625
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176641
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176655
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176669
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176683
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176697
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176711
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176725
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176739
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176753
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176769
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176783
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176797
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176811
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176827
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176841
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176857
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176871
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176885
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176899
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176913
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176929
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176943
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176957
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176971
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041176987
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177001
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177015
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177029
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177045
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177061
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177075
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177089
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177101
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177115
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177129
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177143
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177161
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177175
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177187
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177201
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177215
Principal investigator 1 ModernaTX, Inc. $3,148.47 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177229
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177243
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177259
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177273
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177287
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177301
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177315
Principal investigator 1 ModernaTX, Inc. $3,148.47 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177333
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177349
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177361
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177375
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177389
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177405
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177417
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177431
Principal investigator 1 ModernaTX, Inc. $3,148.47 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177445
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177459
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177475
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177491
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177505
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177521
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177535
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177551
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177565
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177581
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177595
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177609
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177623
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177637
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177651
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177665
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177679
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177693
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177707
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177723
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177737
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177751
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177765
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177779
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177793
Principal investigator 1 ModernaTX, Inc. $1,766.61 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177809
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177821
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177835
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177849
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177865
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177879
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177893
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177905
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177921
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177935
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177949
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177963
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177979
Principal investigator 1 ModernaTX, Inc. $3,148.47 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041177993
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178009
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178025
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178039
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178053
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178067
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178081
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178095
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178109
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178125
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178139
Principal investigator 1 ModernaTX, Inc. $3,148.47 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178153
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178167
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178183
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178199
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178213
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178227
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178241
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178259
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178273
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178291
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178305
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178317
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178333
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178347
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178361
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178375
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178387
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178403
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178419
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178433
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178447
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178461
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178473
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178487
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178501
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178517
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178529
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178545
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178557
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178571
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178587
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178601
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178615
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178629
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178643
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178657
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178671
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178685
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178699
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178713
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178725
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178739
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178755
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178769
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178781
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178795
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178809
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178823
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178837
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178853
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178867
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178881
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178895
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178909
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178923
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178937
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178953
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178967
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178981
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041178997
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179011
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179025
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179039
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179053
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179067
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179081
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179095
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179111
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179125
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179139
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179151
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179165
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179180
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179195
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179209
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179223
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179237
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179251
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179265
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179281
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179295
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179307
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179325
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179337
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179351
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179365
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179379
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179393
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179407
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179423
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179437
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179451
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179465
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179479
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179493
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179507
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179521
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179535
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179549
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179563
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179577
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179591
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179605
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179623
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179637
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179651
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179665
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179683
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179697
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179713
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179727
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179741
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179755
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179769
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179783
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179797
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179811
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179827
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179841
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179855
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179869
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179883
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179901
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179915
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179929
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179941
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179955
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179971
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179983
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041179997
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180011
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180025
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180039
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180055
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180067
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180081
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180095
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180107
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180125
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180137
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180149
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180163
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180177
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180189
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180207
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180219
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180235
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180247
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180255
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180265
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180279
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180293
Principal investigator 1 ModernaTX, Inc. $3,148.47 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180304
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180315
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180323
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180337
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180351
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180365
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180379
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180393
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180409
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180421
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180435
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180449
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180463
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180479
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180493
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180507
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180521
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180533
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180547
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180561
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180575
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180589
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180603
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180617
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180631
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180645
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180661
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180673
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180689
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180705
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180719
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180733
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180747
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180763
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180777
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180789
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180805
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180817
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180831
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180846
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180861
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180875
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180891
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180905
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180919
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180933
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180947
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180961
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180975
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041180989
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181001
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181019
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181033
Principal investigator 1 ModernaTX, Inc. $3,148.47 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181047
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181061
Principal investigator 1 ModernaTX, Inc. $1,766.61 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181075
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181089
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181103
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181117
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181131
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181147
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181161
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181175
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181189
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181203
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181217
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181231
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181245
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181259
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181273
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181289
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181303
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181315
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181329
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181343
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181357
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181371
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181385
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181399
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181411
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181425
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181441
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181453
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181467
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181483
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181497
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181511
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181527
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181541
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181555
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181569
Principal investigator 1 ModernaTX, Inc. $3,148.47 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181583
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181597
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181611
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181627
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181641
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181655
Principal investigator 1 ModernaTX, Inc. $3,148.47 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181669
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181683
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181697
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181707
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181721
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181735
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181747
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181759
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181773
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181787
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181803
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181817
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181831
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181849
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181863
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181877
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181891
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181905
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181919
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181933
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181947
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181961
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181975
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041181989
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182005
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182019
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182033
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182047
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182061
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182075
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182089
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182103
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182117
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182131
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182145
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182159
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182175
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182191
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182205
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182219
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182233
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182247
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182261
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182277
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182293
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182305
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182319
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182333
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182347
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182365
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182379
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182393
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182407
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182421
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182435
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182451
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182465
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182479
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182493
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182507
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182563
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182577
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182590
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182605
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182617
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182631
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182647
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182661
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182675
Principal investigator 1 ModernaTX, Inc. $700.65 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182689
Principal investigator 1 ModernaTX, Inc. $2,053.62 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182703
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182719
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182735
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182749
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182763
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182777
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182791
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182807
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182819
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182833
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182847
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182863
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182877
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182891
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182905
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182919
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182931
Principal investigator 1 ModernaTX, Inc. $3,148.47 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182945
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182959
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182973
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041182987
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183001
Principal investigator 1 ModernaTX, Inc. $3,148.47 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183015
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183029
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183044
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183057
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183071
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183085
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183099
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183113
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183127
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183139
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183155
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183169
Principal investigator 1 ModernaTX, Inc. $3,148.47 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183185
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183199
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183211
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183225
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183241
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183255
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183269
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183283
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183297
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183311
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183327
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183341
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183355
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183369
Principal investigator 1 ModernaTX, Inc. $3,148.47 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183387
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183403
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183417
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183431
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183445
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183459
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183473
Principal investigator 1 ModernaTX, Inc. $3,013.20 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183487
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183502
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183515
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183529
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183543
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183555
Principal investigator 1 ModernaTX, Inc. $801.90 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183569
Principal investigator 1 ModernaTX, Inc. $20.25 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183583
Principal investigator 1 ModernaTX, Inc. $4,745.93 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041183601
Principal investigator 1 ModernaTX, Inc. $2,530.00 06/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041205117
Principal investigator 1 PFIZER INC. $138,849.08 06/14/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046125409
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172235
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172249
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172263
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172275
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172289
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172305
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172319
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172333
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172347
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172361
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172375
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172393
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172409
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172421
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172435
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172935
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172947
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172963
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172977
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172989
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173003
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173017
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173031
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173047
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173061
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173081
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173095
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173109
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173123
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173137
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173151
Principal investigator 1 ModernaTX, Inc. $1,078.33 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173165
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173181
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173195
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173209
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173223
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173239
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173253
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173269
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173283
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173297
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173311
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173327
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173341
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173355
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173369
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173383
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173397
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173411
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173423
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173437
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173451
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173465
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173481
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173497
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173517
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173531
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173545
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173559
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173575
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173589
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173603
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173615
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173631
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173647
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173663
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173679
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173693
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173707
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173721
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173735
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173749
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173765
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173779
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173793
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173807
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173821
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173835
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173851
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173867
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173881
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173895
Principal investigator 1 ModernaTX, Inc. $739.68 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173909
Principal investigator 1 ModernaTX, Inc. $1,078.33 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041173925
Principal investigator 1 ModernaTX, Inc. $168,164.11 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041205803
Principal investigator 1 ModernaTX, Inc. $168,174.67 06/09/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041205817
Principal investigator 1 ModernaTX, Inc. $3,252.00 06/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041205069
Principal investigator 1 ModernaTX, Inc. $1,000.00 06/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041205085
Principal investigator 1 ModernaTX, Inc. $1,000.00 06/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041205845
Principal investigator 1 ModernaTX, Inc. $3,000.00 06/07/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041206973
Principal investigator 1 PFIZER INC. $153,714.75 06/03/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045936031
Principal investigator 1 PFIZER INC. $79,373.65 06/03/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046068487
Principal investigator 1 ModernaTX, Inc. $828.00 06/02/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041205101
Principal investigator 1 ModernaTX, Inc. $7,100.00 06/02/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041206989
Principal investigator 1 ModernaTX, Inc. $270.00 06/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172449
Principal investigator 1 ModernaTX, Inc. $7,341.60 06/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172465
Principal investigator 1 ModernaTX, Inc. $315.00 06/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172479
Principal investigator 1 ModernaTX, Inc. $7,245.00 06/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172491
Principal investigator 1 ModernaTX, Inc. $14,200.20 05/25/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171237
Principal investigator 1 ModernaTX, Inc. $12,751.20 05/25/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171367
Principal investigator 1 ModernaTX, Inc. $12,268.20 05/25/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171383
Principal investigator 1 ModernaTX, Inc. $12,268.20 05/25/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171975
Principal investigator 1 ModernaTX, Inc. $22,024.80 05/25/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171989
Principal investigator 1 ModernaTX, Inc. $22,024.80 05/25/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172145
Principal investigator 1 PFIZER INC. $88,608.57 05/25/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046080035
Principal investigator 1 PFIZER INC. $23,725.94 05/25/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046293239
Principal investigator 1 ModernaTX, Inc. $45.00 05/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171223
Principal investigator 1 ModernaTX, Inc. $45.00 05/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171339
Principal investigator 1 ModernaTX, Inc. $45.00 05/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171353
Principal investigator 1 ModernaTX, Inc. $2,500.00 05/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041171573
Principal investigator 1 ModernaTX, Inc. $300.00 05/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041171585
Principal investigator 1 ModernaTX, Inc. $500.00 05/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041171599
Principal investigator 1 ModernaTX, Inc. $1,000.00 05/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041171657
Principal investigator 1 ModernaTX, Inc. $10,000.00 05/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172005
Principal investigator 1 ModernaTX, Inc. $1,250.00 05/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041172019
Principal investigator 1 ModernaTX, Inc. $45.00 05/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172117
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171091
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171105
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171135
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171147
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171161
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171191
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171207
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171283
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171297
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171323
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171425
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171441
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171455
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171469
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171515
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171529
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171545
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171701
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171715
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171729
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171801
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171817
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171847
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171861
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171875
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171889
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171933
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171948
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171963
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172075
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172089
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172103
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172131
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172203
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/22/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172217
Principal investigator 1 ModernaTX, Inc. $4,057.20 05/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171063
Principal investigator 1 ModernaTX, Inc. $1,159.20 05/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171077
Principal investigator 1 ModernaTX, Inc. $5,602.80 05/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171119
Principal investigator 1 ModernaTX, Inc. $7,245.00 05/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171177
Principal investigator 1 ModernaTX, Inc. $7,245.00 05/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171251
Principal investigator 1 ModernaTX, Inc. $289.80 05/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171265
Principal investigator 1 ModernaTX, Inc. $5,602.80 05/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171311
Principal investigator 1 ModernaTX, Inc. $7,341.60 05/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171397
Principal investigator 1 ModernaTX, Inc. $96.60 05/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171411
Principal investigator 1 ModernaTX, Inc. $5,602.80 05/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171483
Principal investigator 1 ModernaTX, Inc. $5,023.20 05/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171499
Principal investigator 1 ModernaTX, Inc. $10,336.20 05/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171559
Principal investigator 1 ModernaTX, Inc. $16,615.20 05/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171615
Principal investigator 1 ModernaTX, Inc. $8,597.40 05/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171629
Principal investigator 1 ModernaTX, Inc. $11,205.60 05/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171643
Principal investigator 1 ModernaTX, Inc. $5,409.60 05/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171671
Principal investigator 1 ModernaTX, Inc. $2,608.20 05/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171685
Principal investigator 1 ModernaTX, Inc. $7,245.00 05/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171743
Principal investigator 1 ModernaTX, Inc. $1,545.60 05/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171759
Principal investigator 1 ModernaTX, Inc. $9,177.00 05/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171773
Principal investigator 1 ModernaTX, Inc. $5,119.80 05/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171788
Principal investigator 1 ModernaTX, Inc. $18,257.40 05/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171833
Principal investigator 1 ModernaTX, Inc. $17,388.00 05/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171903
Principal investigator 1 ModernaTX, Inc. $5,119.80 05/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041171917
Principal investigator 1 ModernaTX, Inc. $31,878.00 05/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172033
Principal investigator 1 ModernaTX, Inc. $7,824.60 05/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172047
Principal investigator 1 ModernaTX, Inc. $96.60 05/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172061
Principal investigator 1 ModernaTX, Inc. $18,160.80 05/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172177
Principal investigator 1 ModernaTX, Inc. $289.80 05/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172189
Principal investigator 1 ModernaTX, Inc. $45.00 05/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041169769
Principal investigator 1 ModernaTX, Inc. $45.00 05/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041169869
Principal investigator 1 ModernaTX, Inc. $45.00 05/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041169941
Principal investigator 1 ModernaTX, Inc. $45.00 05/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041169997
Principal investigator 1 ModernaTX, Inc. $45.00 05/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170341
Principal investigator 1 ModernaTX, Inc. $45.00 05/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170356
Principal investigator 1 ModernaTX, Inc. $45.00 05/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170399
Principal investigator 1 ModernaTX, Inc. $45.00 05/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041172163
Principal investigator 1 ModernaTX, Inc. $7,631.40 05/11/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041169695
Principal investigator 1 ModernaTX, Inc. $14,876.40 05/11/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041169755
Principal investigator 1 ModernaTX, Inc. $386.40 05/11/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041169915
Principal investigator 1 ModernaTX, Inc. $11,978.40 05/11/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041169929
Principal investigator 1 ModernaTX, Inc. $193.20 05/11/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170041
Principal investigator 1 ModernaTX, Inc. $193.20 05/11/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170055
Principal investigator 1 ModernaTX, Inc. $193.20 05/11/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170069
Principal investigator 1 ModernaTX, Inc. $96.60 05/11/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170097
Principal investigator 1 ModernaTX, Inc. $12,171.60 05/11/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170111
Principal investigator 1 ModernaTX, Inc. $7,341.60 05/11/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170167
Principal investigator 1 ModernaTX, Inc. $14,586.60 05/11/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170325
Principal investigator 1 ModernaTX, Inc. $13,234.20 05/11/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170519
Principal investigator 1 ModernaTX, Inc. $8,404.20 05/11/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170533
Principal investigator 1 PFIZER INC. $52,484.12 05/09/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045956611
Principal investigator 1 ModernaTX, Inc. $17,967.60 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041169619
Principal investigator 1 ModernaTX, Inc. $8,694.00 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041169635
Principal investigator 1 ModernaTX, Inc. $739.68 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041169650
Principal investigator 1 ModernaTX, Inc. $739.68 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041169665
Principal investigator 1 ModernaTX, Inc. $739.68 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041169683
Principal investigator 1 ModernaTX, Inc. $17,001.60 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041169709
Principal investigator 1 ModernaTX, Inc. $739.68 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041169723
Principal investigator 1 ModernaTX, Inc. $739.68 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041169741
Principal investigator 1 ModernaTX, Inc. $17,484.60 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041169783
Principal investigator 1 ModernaTX, Inc. $6,182.40 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041169797
Principal investigator 1 ModernaTX, Inc. $13,041.00 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041169811
Principal investigator 1 ModernaTX, Inc. $7,245.00 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041169825
Principal investigator 1 ModernaTX, Inc. $739.68 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041169839
Principal investigator 1 ModernaTX, Inc. $739.68 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041169853
Principal investigator 1 ModernaTX, Inc. $7,438.20 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041169887
Principal investigator 1 ModernaTX, Inc. $7,534.80 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041169901
Principal investigator 1 ModernaTX, Inc. $6,858.60 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041169955
Principal investigator 1 ModernaTX, Inc. $13,524.00 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041169969
Principal investigator 1 ModernaTX, Inc. $739.68 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041169983
Principal investigator 1 ModernaTX, Inc. $7,728.00 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170011
Principal investigator 1 ModernaTX, Inc. $739.68 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170027
Principal investigator 1 ModernaTX, Inc. $739.68 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170083
Principal investigator 1 ModernaTX, Inc. $6,279.00 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170125
Principal investigator 1 ModernaTX, Inc. $739.68 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170139
Principal investigator 1 ModernaTX, Inc. $739.68 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170153
Principal investigator 1 ModernaTX, Inc. $739.68 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170183
Principal investigator 1 ModernaTX, Inc. $739.68 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170200
Principal investigator 1 ModernaTX, Inc. $739.68 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170215
Principal investigator 1 ModernaTX, Inc. $739.68 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170227
Principal investigator 1 ModernaTX, Inc. $17,967.60 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170241
Principal investigator 1 ModernaTX, Inc. $739.68 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170255
Principal investigator 1 ModernaTX, Inc. $739.68 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170269
Principal investigator 1 ModernaTX, Inc. $739.68 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170283
Principal investigator 1 ModernaTX, Inc. $739.68 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170299
Principal investigator 1 ModernaTX, Inc. $739.68 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170311
Principal investigator 1 ModernaTX, Inc. $23,184.00 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170371
Principal investigator 1 ModernaTX, Inc. $12,558.00 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170385
Principal investigator 1 ModernaTX, Inc. $12,268.20 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170413
Principal investigator 1 ModernaTX, Inc. $5,602.80 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170427
Principal investigator 1 ModernaTX, Inc. $739.68 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170445
Principal investigator 1 ModernaTX, Inc. $739.68 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170459
Principal investigator 1 ModernaTX, Inc. $739.68 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170471
Principal investigator 1 ModernaTX, Inc. $739.68 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170487
Principal investigator 1 ModernaTX, Inc. $739.68 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170503
Principal investigator 1 ModernaTX, Inc. $19,320.00 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170543
Principal investigator 1 ModernaTX, Inc. $23,184.00 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170863
Principal investigator 1 ModernaTX, Inc. $739.68 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170877
Principal investigator 1 ModernaTX, Inc. $739.68 05/08/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041170893
Principal investigator 1 PFIZER INC. $88,630.03 05/06/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046311879
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041165291
Principal investigator 1 ModernaTX, Inc. $3,013.20 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041165305
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041165323
Principal investigator 1 ModernaTX, Inc. $3,148.47 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041165339
Principal investigator 1 ModernaTX, Inc. $3,148.47 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041165353
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041165367
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041165381
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041165395
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041165409
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041165423
Principal investigator 1 ModernaTX, Inc. $700.65 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041165437
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041165451
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041165465
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041165483
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041165499
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041165513
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041165527
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041165541
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041165555
Principal investigator 1 ModernaTX, Inc. $3,013.20 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041165569
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041165583
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041165597
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041165609
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041165621
Principal investigator 1 ModernaTX, Inc. $3,013.20 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041165637
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041165651
Principal investigator 1 ModernaTX, Inc. $3,148.47 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041165665
Principal investigator 1 ModernaTX, Inc. $3,013.20 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041165679
Principal investigator 1 ModernaTX, Inc. $3,148.47 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041165693
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041166733
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041166747
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041166763
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041166777
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041166791
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041166805
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041166819
Principal investigator 1 ModernaTX, Inc. $3,013.20 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041166835
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041166849
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041166865
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041166879
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041166893
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041166907
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041166921
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041166933
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041166953
Principal investigator 1 ModernaTX, Inc. $3,013.20 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041166967
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041166981
Principal investigator 1 ModernaTX, Inc. $3,013.20 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041166995
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167009
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167023
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167037
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167053
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167069
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167083
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167097
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167111
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167127
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167141
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167155
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167169
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167183
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167197
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167211
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167225
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167239
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167255
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167271
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167285
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167299
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167313
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167327
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167341
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167355
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167369
Principal investigator 1 ModernaTX, Inc. $3,148.47 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167383
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167397
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167411
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167427
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167443
Principal investigator 1 ModernaTX, Inc. $3,148.47 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167457
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167471
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167485
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167499
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167513
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167527
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167543
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167557
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167569
Principal investigator 1 ModernaTX, Inc. $3,148.47 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167585
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167597
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167611
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167627
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167641
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167655
Principal investigator 1 ModernaTX, Inc. $3,148.47 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167669
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167683
Principal investigator 1 ModernaTX, Inc. $3,148.47 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167697
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167711
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167727
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167741
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167755
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167769
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167783
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167797
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167815
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167825
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167843
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167857
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167871
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167889
Principal investigator 1 ModernaTX, Inc. $3,013.20 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167903
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167919
Principal investigator 1 ModernaTX, Inc. $3,148.47 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167933
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167947
Principal investigator 1 ModernaTX, Inc. $700.65 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167961
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167975
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041167991
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168003
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168019
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168033
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168047
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168061
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168077
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168091
Principal investigator 1 ModernaTX, Inc. $3,148.47 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168105
Principal investigator 1 ModernaTX, Inc. $3,013.20 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168119
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168133
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168147
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168163
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168177
Principal investigator 1 ModernaTX, Inc. $3,148.47 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168191
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168207
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168221
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168235
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168249
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168263
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168277
Principal investigator 1 ModernaTX, Inc. $4,745.93 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168291
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168305
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168320
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168335
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168349
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168365
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168379
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168393
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168407
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168421
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168435
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168449
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168463
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168477
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168491
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168505
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168521
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168535
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168549
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168565
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168579
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168593
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168607
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168621
Principal investigator 1 ModernaTX, Inc. $3,148.47 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168635
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168649
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168663
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168677
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168693
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168705
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168721
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168735
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168747
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168761
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168777
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168793
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168807
Principal investigator 1 ModernaTX, Inc. $700.65 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168821
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168835
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168851
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168867
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168881
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168895
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168909
Principal investigator 1 ModernaTX, Inc. $3,013.20 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168923
Principal investigator 1 ModernaTX, Inc. $3,148.47 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168939
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168953
Principal investigator 1 ModernaTX, Inc. $3,148.47 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168968
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168983
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041168999
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169013
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169027
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169041
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169055
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169069
Principal investigator 1 ModernaTX, Inc. $3,148.47 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169083
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169097
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169109
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169123
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169139
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169155
Principal investigator 1 ModernaTX, Inc. $3,148.47 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169169
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169182
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169195
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169211
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169225
Principal investigator 1 ModernaTX, Inc. $3,148.47 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169241
Principal investigator 1 ModernaTX, Inc. $3,148.47 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169255
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169269
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169283
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169297
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169311
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169323
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169339
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169353
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169369
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169383
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169397
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169411
Principal investigator 1 ModernaTX, Inc. $3,013.20 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169427
Principal investigator 1 ModernaTX, Inc. $3,013.20 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169439
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169453
Principal investigator 1 ModernaTX, Inc. $3,148.47 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169469
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169483
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169501
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169517
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169533
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169547
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169559
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169577
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169591
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041169605
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041170559
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041170573
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041170589
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041170604
Principal investigator 1 ModernaTX, Inc. $700.65 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041170619
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041170633
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041170645
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041170661
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041170675
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041170689
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041170705
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041170719
Principal investigator 1 ModernaTX, Inc. $3,148.47 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041170733
Principal investigator 1 ModernaTX, Inc. $3,148.47 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041170747
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041170761
Principal investigator 1 ModernaTX, Inc. $3,013.20 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041170775
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041170789
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041170805
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041170821
Principal investigator 1 ModernaTX, Inc. $801.90 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041170835
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041170849
Principal investigator 1 ModernaTX, Inc. $3,148.47 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041170907
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041170921
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041170935
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041170949
Principal investigator 1 ModernaTX, Inc. $3,013.20 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041170963
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041170977
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041170991
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041171005
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041171019
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041171035
Principal investigator 1 ModernaTX, Inc. $20.25 05/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041171049
Principal investigator 1 ModernaTX, Inc. $166.50 05/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041145205
Principal investigator 1 ModernaTX, Inc. $9,080.40 05/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165707
Principal investigator 1 ModernaTX, Inc. $14,586.60 05/04/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165721
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041162622
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041162637
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041162653
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041162667
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041162681
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041162703
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041162717
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041162730
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041162745
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041162761
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041162775
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041162789
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041162803
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041162819
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041162833
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041162847
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041162861
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041162875
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041162889
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041162905
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041162919
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041162935
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041162951
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041162965
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041162981
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041162999
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163013
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163027
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163041
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163055
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163067
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163081
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163095
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163109
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163125
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163141
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163153
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163171
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163185
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163199
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163213
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163227
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163241
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163255
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163271
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163285
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163299
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163313
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163327
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163339
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163357
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163371
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163383
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163397
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163413
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163427
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163439
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163455
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163469
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163485
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163499
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163513
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163529
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163545
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163559
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163573
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163587
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163601
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163615
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163629
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163645
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163657
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163675
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163689
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163703
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163717
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163731
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163745
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163761
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163775
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163789
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163803
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163817
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163831
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163845
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163863
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163879
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163893
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163907
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163921
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163935
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163949
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163963
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163977
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041163991
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164005
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164021
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164037
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164053
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164067
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164081
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164095
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164109
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164121
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164137
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164151
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164165
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164183
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164197
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164209
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164225
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164241
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164255
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164269
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164283
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164297
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164311
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164327
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164339
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164353
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164367
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164381
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164395
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164409
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164423
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164437
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164451
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164465
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164481
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164495
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164507
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164523
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164537
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164551
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164567
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164581
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164595
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164611
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164625
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164639
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164655
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164667
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164681
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164695
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164709
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164725
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164739
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164751
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164763
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164776
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164789
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164805
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164819
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164829
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164843
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164851
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164865
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164879
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164893
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164905
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164919
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164939
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164953
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164967
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164977
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041164991
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165005
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165019
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165035
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165049
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165063
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165079
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165093
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165105
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165119
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165133
Principal investigator 1 ModernaTX, Inc. $146.28 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165149
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165164
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165179
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165193
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165207
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165221
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165235
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165249
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165263
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165277
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165737
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165751
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165765
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165779
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165795
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165810
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165823
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165835
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165853
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165867
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165881
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165895
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165909
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165925
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165939
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165953
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165967
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165981
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041165995
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166009
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166023
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166037
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166053
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166067
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166081
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166095
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166109
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166123
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166137
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166151
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166167
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166181
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166197
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166209
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166223
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166239
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166255
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166269
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166283
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166297
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166311
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166327
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166341
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166355
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166369
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166383
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166397
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166411
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166427
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166441
Principal investigator 1 ModernaTX, Inc. $39.20 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166455
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166473
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166487
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166501
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166515
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166529
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166543
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166557
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166575
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166591
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166605
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166619
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166631
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166647
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166661
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166675
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166689
Principal investigator 1 ModernaTX, Inc. $1,078.33 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166703
Principal investigator 1 ModernaTX, Inc. $739.68 05/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041166717
Principal investigator 1 PFIZER INC. $68,724.39 04/25/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046042223
Principal investigator 1 ModernaTX, Inc. $4,745.93 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160393
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160407
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160421
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160435
Principal investigator 1 ModernaTX, Inc. $3,148.47 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160449
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160465
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160479
Principal investigator 1 ModernaTX, Inc. $3,013.20 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160493
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160507
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160523
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160535
Principal investigator 1 ModernaTX, Inc. $3,013.20 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160551
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160565
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160581
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160593
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160607
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160623
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160637
Principal investigator 1 ModernaTX, Inc. $4,745.93 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160665
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160679
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160693
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160707
Principal investigator 1 ModernaTX, Inc. $3,148.47 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160721
Principal investigator 1 ModernaTX, Inc. $3,013.20 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160735
Principal investigator 1 ModernaTX, Inc. $3,148.47 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160749
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160763
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160777
Principal investigator 1 ModernaTX, Inc. $3,013.20 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160791
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160805
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160819
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160833
Principal investigator 1 ModernaTX, Inc. $3,148.47 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160847
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160865
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160977
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041160991
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161005
Principal investigator 1 ModernaTX, Inc. $3,148.47 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161021
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161035
Principal investigator 1 ModernaTX, Inc. $4,745.93 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161049
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161063
Principal investigator 1 ModernaTX, Inc. $3,013.20 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161079
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161095
Principal investigator 1 ModernaTX, Inc. $4,745.93 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161107
Principal investigator 1 ModernaTX, Inc. $3,148.47 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161121
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161135
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161151
Principal investigator 1 ModernaTX, Inc. $3,013.20 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161167
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161181
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161196
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161209
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161223
Principal investigator 1 ModernaTX, Inc. $3,148.47 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161237
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161253
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161267
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161281
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161297
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161309
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161327
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161341
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161357
Principal investigator 1 ModernaTX, Inc. $4,745.93 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161369
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161383
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161397
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161413
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161427
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161441
Principal investigator 1 ModernaTX, Inc. $4,745.93 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161455
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161471
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161487
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161501
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161515
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161531
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161545
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161559
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161573
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161587
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161603
Principal investigator 1 ModernaTX, Inc. $4,745.93 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161617
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161631
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161645
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161659
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161673
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161687
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161701
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161715
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161731
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161745
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161759
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161775
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161787
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161801
Principal investigator 1 ModernaTX, Inc. $4,745.93 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161817
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161831
Principal investigator 1 ModernaTX, Inc. $3,148.47 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161845
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161859
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161873
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161887
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161901
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161915
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161929
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161943
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161957
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161971
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161985
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041161999
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162015
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162031
Principal investigator 1 ModernaTX, Inc. $3,148.47 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162045
Principal investigator 1 ModernaTX, Inc. $3,148.47 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162057
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162071
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162087
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162101
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162117
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162131
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162143
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162157
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162173
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162187
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162201
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162215
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162229
Principal investigator 1 ModernaTX, Inc. $3,013.20 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162243
Principal investigator 1 ModernaTX, Inc. $3,148.47 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162259
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162275
Principal investigator 1 ModernaTX, Inc. $3,148.47 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162287
Principal investigator 1 ModernaTX, Inc. $4,745.93 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162301
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162317
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162331
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162345
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162359
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162373
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162387
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162403
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162417
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162431
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162445
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162459
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162473
Principal investigator 1 ModernaTX, Inc. $4,745.93 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162489
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162507
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162521
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162535
Principal investigator 1 ModernaTX, Inc. $3,148.47 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162549
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162563
Principal investigator 1 ModernaTX, Inc. $4,745.93 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162577
Principal investigator 1 ModernaTX, Inc. $4,745.93 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162593
Principal investigator 1 ModernaTX, Inc. $20.25 04/21/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041162607
Principal investigator 1 ModernaTX, Inc. $415.00 04/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160651
Principal investigator 1 ModernaTX, Inc. $415.00 04/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160879
Principal investigator 1 ModernaTX, Inc. $75.00 04/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160893
Principal investigator 1 ModernaTX, Inc. $75.00 04/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160909
Principal investigator 1 ModernaTX, Inc. $75.00 04/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160923
Principal investigator 1 ModernaTX, Inc. $75.00 04/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160963
Principal investigator 1 ModernaTX, Inc. $500.00 04/14/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160937
Principal investigator 1 PFIZER INC. $31,584.12 04/12/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046292623
Principal investigator 1 ModernaTX, Inc. $33.50 04/11/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041784243
Principal investigator 1 ModernaTX, Inc. $415.00 04/05/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160949
Principal investigator 1 PFIZER INC. $90,163.56 04/05/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046300395
Principal investigator 1 ModernaTX, Inc. $250.00 03/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159545
Principal investigator 1 ModernaTX, Inc. $2,525.40 03/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159587
Principal investigator 1 ModernaTX, Inc. $250.00 03/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159643
Principal investigator 1 ModernaTX, Inc. $250.00 03/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159681
Principal investigator 1 ModernaTX, Inc. $250.00 03/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159801
Principal investigator 1 ModernaTX, Inc. $250.00 03/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160017
Principal investigator 1 ModernaTX, Inc. $75.00 03/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160379
Principal investigator 1 ModernaTX, Inc. $2,525.40 03/29/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159657
Principal investigator 1 PFIZER INC. $102,747.75 03/24/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046127785
Principal investigator 1 ModernaTX, Inc. $2,525.40 03/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159559
Principal investigator 1 ModernaTX, Inc. $2,455.02 03/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159573
Principal investigator 1 ModernaTX, Inc. $2,525.40 03/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159601
Principal investigator 1 ModernaTX, Inc. $2,525.40 03/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159615
Principal investigator 1 ModernaTX, Inc. $2,525.40 03/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159629
Principal investigator 1 ModernaTX, Inc. $2,684.10 03/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159667
Principal investigator 1 ModernaTX, Inc. $2,525.40 03/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160289
Principal investigator 1 ModernaTX, Inc. $2,455.02 03/17/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160317
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158107
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158123
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158139
Principal investigator 1 ModernaTX, Inc. $13.80 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158167
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158179
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158193
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158207
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158235
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158251
Principal investigator 1 ModernaTX, Inc. $2,547.48 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158267
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158281
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158295
Principal investigator 1 ModernaTX, Inc. $13.80 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158309
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158323
Principal investigator 1 ModernaTX, Inc. $13.80 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158337
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158351
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158365
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158379
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158421
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158435
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158449
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158463
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158493
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158509
Principal investigator 1 ModernaTX, Inc. $13.80 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158539
Principal investigator 1 ModernaTX, Inc. $13.80 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158551
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158565
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158579
Principal investigator 1 ModernaTX, Inc. $1,078.33 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158595
Principal investigator 1 ModernaTX, Inc. $1,078.33 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158609
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158621
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158637
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158651
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158665
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158681
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158695
Principal investigator 1 ModernaTX, Inc. $13.80 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158707
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158719
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158737
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158751
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158765
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158793
Principal investigator 1 ModernaTX, Inc. $1,078.33 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158805
Principal investigator 1 ModernaTX, Inc. $1,078.33 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158821
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158835
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158849
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158863
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158877
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158891
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158907
Principal investigator 1 ModernaTX, Inc. $1,078.33 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158935
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158949
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158963
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158977
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158993
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159007
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159023
Principal investigator 1 ModernaTX, Inc. $1,078.33 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159037
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159051
Principal investigator 1 ModernaTX, Inc. $13.80 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159169
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159183
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159197
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159215
Principal investigator 1 ModernaTX, Inc. $13.80 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159233
Principal investigator 1 ModernaTX, Inc. $1,078.33 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159249
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159697
Principal investigator 1 ModernaTX, Inc. $13.80 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159711
Principal investigator 1 ModernaTX, Inc. $13.80 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159728
Principal investigator 1 ModernaTX, Inc. $1,078.33 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159745
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159761
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159775
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159789
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159813
Principal investigator 1 ModernaTX, Inc. $13.80 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159827
Principal investigator 1 ModernaTX, Inc. $13.80 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159843
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159859
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159873
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159887
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159901
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159915
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159931
Principal investigator 1 ModernaTX, Inc. $13.80 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159945
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159960
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159973
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159987
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160003
Principal investigator 1 ModernaTX, Inc. $13.80 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160033
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160047
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160061
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160075
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160089
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160103
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160117
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160131
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160145
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160159
Principal investigator 1 ModernaTX, Inc. $13.80 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160173
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160187
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160203
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160217
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160233
Principal investigator 1 ModernaTX, Inc. $13.80 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160247
Principal investigator 1 ModernaTX, Inc. $1,078.33 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160261
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160275
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160303
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160335
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160349
Principal investigator 1 ModernaTX, Inc. $739.68 03/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041160363
Principal investigator 1 ModernaTX, Inc. $2,525.40 03/10/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158153
Principal investigator 1 ModernaTX, Inc. $2,114.16 03/10/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158221
Principal investigator 1 ModernaTX, Inc. $2,525.40 03/10/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158393
Principal investigator 1 ModernaTX, Inc. $2,525.40 03/10/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158407
Principal investigator 1 ModernaTX, Inc. $2,525.40 03/10/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158477
Principal investigator 1 ModernaTX, Inc. $2,525.40 03/10/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158525
Principal investigator 1 ModernaTX, Inc. $2,114.16 03/10/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158779
Principal investigator 1 ModernaTX, Inc. $2,043.78 03/10/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158919
Principal investigator 1 ModernaTX, Inc. $2,272.86 03/10/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159155
Principal investigator 1 ModernaTX, Inc. $2,525.40 03/10/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159335
Principal investigator 1 ModernaTX, Inc. $2,043.78 03/10/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159485
Principal investigator 1 ModernaTX, Inc. $2,114.16 03/10/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159499
Principal investigator 1 ModernaTX, Inc. $2,114.16 03/10/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159515
Principal investigator 1 PFIZER INC. $5,071.50 03/09/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046187959
Principal investigator 1 PFIZER INC. $4,226.25 03/07/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045935737
Principal investigator 1 PFIZER INC. $94,653.00 03/04/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1045941909
Principal investigator 1 ModernaTX, Inc. $158.70 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157905
Principal investigator 1 ModernaTX, Inc. $262.20 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157919
Principal investigator 1 ModernaTX, Inc. $158.70 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157933
Principal investigator 1 ModernaTX, Inc. $262.20 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157947
Principal investigator 1 ModernaTX, Inc. $262.20 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157961
Principal investigator 1 ModernaTX, Inc. $158.70 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157981
Principal investigator 1 ModernaTX, Inc. $262.20 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157995
Principal investigator 1 ModernaTX, Inc. $158.70 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158011
Principal investigator 1 ModernaTX, Inc. $262.20 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158023
Principal investigator 1 ModernaTX, Inc. $262.20 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158037
Principal investigator 1 ModernaTX, Inc. $158.70 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158055
Principal investigator 1 ModernaTX, Inc. $262.20 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158069
Principal investigator 1 ModernaTX, Inc. $158.70 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041158087
Principal investigator 1 ModernaTX, Inc. $158.70 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159067
Principal investigator 1 ModernaTX, Inc. $158.70 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159085
Principal investigator 1 ModernaTX, Inc. $262.20 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159099
Principal investigator 1 ModernaTX, Inc. $262.20 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159113
Principal investigator 1 ModernaTX, Inc. $262.20 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159127
Principal investigator 1 ModernaTX, Inc. $262.20 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159141
Principal investigator 1 ModernaTX, Inc. $158.70 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159263
Principal investigator 1 ModernaTX, Inc. $262.20 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159277
Principal investigator 1 ModernaTX, Inc. $262.20 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159291
Principal investigator 1 ModernaTX, Inc. $262.20 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159305
Principal investigator 1 ModernaTX, Inc. $262.20 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159321
Principal investigator 1 ModernaTX, Inc. $158.70 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159349
Principal investigator 1 ModernaTX, Inc. $262.20 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159365
Principal investigator 1 ModernaTX, Inc. $262.20 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159379
Principal investigator 1 ModernaTX, Inc. $262.20 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159393
Principal investigator 1 ModernaTX, Inc. $158.70 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159401
Principal investigator 1 ModernaTX, Inc. $158.70 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159415
Principal investigator 1 ModernaTX, Inc. $158.70 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159429
Principal investigator 1 ModernaTX, Inc. $158.70 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159443
Principal investigator 1 ModernaTX, Inc. $262.20 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159457
Principal investigator 1 ModernaTX, Inc. $262.20 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159471
Principal investigator 1 ModernaTX, Inc. $262.20 03/01/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041159531
Principal investigator 1 PFIZER INC. $287,868.00 02/28/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046060019
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152341
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152359
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152373
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152387
Principal investigator 1 ModernaTX, Inc. $1,078.33 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152401
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152415
Principal investigator 1 ModernaTX, Inc. $812.82 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152435
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152449
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152463
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152477
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152491
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152505
Principal investigator 1 ModernaTX, Inc. $666.54 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152519
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152533
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152547
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152565
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152579
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152593
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152607
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152621
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152637
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152649
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152663
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152677
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152695
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152709
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152723
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152737
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152793
Principal investigator 1 ModernaTX, Inc. $812.82 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152807
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152821
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152837
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152851
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152865
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152879
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152893
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152907
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152921
Principal investigator 1 ModernaTX, Inc. $666.54 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152937
Principal investigator 1 ModernaTX, Inc. $666.54 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152951
Principal investigator 1 ModernaTX, Inc. $666.54 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152965
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153773
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153789
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153801
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153819
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153829
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153845
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153857
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153873
Principal investigator 1 ModernaTX, Inc. $1,078.33 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153887
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153901
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153915
Principal investigator 1 ModernaTX, Inc. $812.82 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153929
Principal investigator 1 ModernaTX, Inc. $666.54 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153941
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153957
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153971
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153985
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153999
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154013
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154027
Principal investigator 1 ModernaTX, Inc. $666.54 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154039
Principal investigator 1 ModernaTX, Inc. $1,078.33 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154057
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154073
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154089
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154103
Principal investigator 1 ModernaTX, Inc. $666.54 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154115
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154131
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154145
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154159
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154173
Principal investigator 1 ModernaTX, Inc. $666.54 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154187
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154201
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154215
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154229
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154243
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154261
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154273
Principal investigator 1 ModernaTX, Inc. $666.54 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154287
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154301
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154315
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154331
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154345
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154359
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154377
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154391
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154405
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154419
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154433
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154449
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154461
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154475
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154489
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154503
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154519
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154535
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154547
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154563
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154577
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154591
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154605
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154619
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154635
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154647
Principal investigator 1 ModernaTX, Inc. $1,078.33 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154661
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154677
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154693
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154707
Principal investigator 1 ModernaTX, Inc. $666.54 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154721
Principal investigator 1 ModernaTX, Inc. $812.82 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154737
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154751
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154765
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154779
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154793
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154809
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154823
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154839
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154855
Principal investigator 1 ModernaTX, Inc. $666.54 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154869
Principal investigator 1 ModernaTX, Inc. $666.54 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154883
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154897
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154911
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154925
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154939
Principal investigator 1 ModernaTX, Inc. $1,078.33 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154953
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154967
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154983
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041154999
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155013
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155027
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155041
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155057
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155071
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155085
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155099
Principal investigator 1 ModernaTX, Inc. $666.54 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155113
Principal investigator 1 ModernaTX, Inc. $666.54 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155127
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155141
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155155
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155169
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155183
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155197
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155211
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155227
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155241
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155257
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155275
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155287
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155301
Principal investigator 1 ModernaTX, Inc. $666.54 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155317
Principal investigator 1 ModernaTX, Inc. $812.82 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155331
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155345
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155357
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155371
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155387
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155403
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155419
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155433
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155447
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155461
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155475
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155489
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155503
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155517
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155533
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155549
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155561
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155575
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155590
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155605
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155621
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155637
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155651
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155665
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155679
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155693
Principal investigator 1 ModernaTX, Inc. $666.54 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155709
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155723
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155737
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155751
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155767
Principal investigator 1 ModernaTX, Inc. $1,078.33 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155781
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155796
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155811
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155827
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155841
Principal investigator 1 ModernaTX, Inc. $1,078.33 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155855
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155871
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155887
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155899
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155915
Principal investigator 1 ModernaTX, Inc. $666.54 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155929
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155943
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155957
Principal investigator 1 ModernaTX, Inc. $1,078.33 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155977
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041155991
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156005
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156019
Principal investigator 1 ModernaTX, Inc. $666.54 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156033
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156051
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156065
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156079
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156093
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156107
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156121
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156137
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156151
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156165
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156181
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156195
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156209
Principal investigator 1 ModernaTX, Inc. $666.54 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156223
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156237
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156253
Principal investigator 1 ModernaTX, Inc. $666.54 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156267
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156285
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156299
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156313
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156327
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156341
Principal investigator 1 ModernaTX, Inc. $666.54 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156355
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156369
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156383
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156397
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156411
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156425
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156439
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156453
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156471
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156487
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156499
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156513
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156527
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156541
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156555
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156571
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156587
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156599
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156614
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156629
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156641
Principal investigator 1 ModernaTX, Inc. $666.54 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156655
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156671
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156685
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156701
Principal investigator 1 ModernaTX, Inc. $1,078.33 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156713
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156727
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156741
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156755
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156769
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156783
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156799
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156815
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156827
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156841
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156853
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156867
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156881
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156895
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156909
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156923
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156937
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156951
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156965
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156983
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041156995
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157011
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157025
Principal investigator 1 ModernaTX, Inc. $1,078.33 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157039
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157053
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157067
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157081
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157095
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157109
Principal investigator 1 ModernaTX, Inc. $1,078.33 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157123
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157135
Principal investigator 1 ModernaTX, Inc. $666.54 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157149
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157163
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157173
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157187
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157195
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157205
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157221
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157234
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157249
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157263
Principal investigator 1 ModernaTX, Inc. $13.80 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157277
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157293
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157305
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157319
Principal investigator 1 ModernaTX, Inc. $666.54 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157335
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157349
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157363
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157377
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157391
Principal investigator 1 ModernaTX, Inc. $1,078.33 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157405
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157421
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157435
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157449
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157465
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157479
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157493
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157509
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157525
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157539
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157553
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157567
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157585
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157599
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157613
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157627
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157641
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157657
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157671
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157685
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157699
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157715
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157729
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157745
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157759
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157773
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157791
Principal investigator 1 ModernaTX, Inc. $666.54 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157805
Principal investigator 1 ModernaTX, Inc. $666.54 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157821
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157835
Principal investigator 1 ModernaTX, Inc. $739.68 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157849
Principal investigator 1 ModernaTX, Inc. $666.54 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157863
Principal investigator 1 ModernaTX, Inc. $666.54 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157875
Principal investigator 1 ModernaTX, Inc. $666.54 02/24/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041157891
Principal investigator 1 PFIZER INC. $36,518.35 02/24/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046201917
Principal investigator 1 PFIZER INC. $13,489.58 02/18/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046146215
Principal investigator 1 PFIZER INC. $2,512.29 02/17/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046295115
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150959
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150975
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150989
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151047
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151057
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152751
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152765
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152779
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152981
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152995
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153007
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153021
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153035
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153053
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153067
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153081
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153091
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153109
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153121
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153133
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153147
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153163
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153175
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153189
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153205
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153219
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153233
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153245
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153259
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153273
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153287
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153303
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153317
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153332
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153345
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153359
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153377
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153391
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153405
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153419
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153433
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153447
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153461
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153475
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153489
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153503
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153519
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153535
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153551
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153563
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153577
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153591
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153605
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153619
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153633
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153647
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153661
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153675
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153689
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153703
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153717
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153731
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153747
Principal investigator 1 ModernaTX, Inc. $96.60 02/16/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041153759
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150917
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150931
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150947
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151005
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151019
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151033
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151071
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151085
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151101
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151115
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151127
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151141
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151155
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151171
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151185
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151199
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151211
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151225
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151241
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151255
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151269
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151283
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151295
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151311
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151329
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151441
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151453
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151583
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151695
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151709
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151723
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151739
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151753
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151767
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151907
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151925
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151999
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152013
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152027
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152109
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152125
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152165
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152181
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152195
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152209
Principal investigator 1 ModernaTX, Inc. $73.14 02/13/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152327
Principal investigator 1 PFIZER INC. $10,021.24 02/10/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046000423
Principal investigator 1 PFIZER INC. $102,179.18 02/07/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045951873
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150295
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150309
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150325
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150339
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150353
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150365
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150379
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150395
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150411
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150425
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150439
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150453
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150469
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150483
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150499
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150513
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150527
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150541
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150557
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150571
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150585
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150599
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150612
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150629
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150645
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150659
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150672
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150687
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150701
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150717
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150731
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150745
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150763
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150777
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150791
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150807
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150821
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150835
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150849
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150863
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150877
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150891
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150905
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151343
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151357
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151371
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151385
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151399
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151413
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151427
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151463
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151481
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151497
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151513
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151527
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151541
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151555
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151569
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151597
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151611
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151625
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151639
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151653
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151667
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151681
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151781
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151797
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151811
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151825
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151837
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151851
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151867
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151881
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151893
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151939
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151955
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151969
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041151983
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152041
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152055
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152069
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152081
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152095
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152138
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152151
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152225
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152243
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152259
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152273
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152285
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152299
Principal investigator 1 ModernaTX, Inc. $96.60 02/06/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041152313
Principal investigator 1 PFIZER INC. $11,326.00 02/04/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046040961
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148071
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148083
Principal investigator 1 ModernaTX, Inc. $75.00 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148097
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148125
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148137
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148153
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148169
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148181
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148197
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148239
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148253
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148269
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148283
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148299
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148315
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148329
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148343
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148371
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148385
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148403
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148445
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148461
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148475
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148489
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148503
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148516
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148531
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148545
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148559
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148573
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148587
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148601
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148616
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148629
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148643
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148657
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149497
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149507
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149523
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149537
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149551
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149561
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149575
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149589
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149601
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149615
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149629
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149643
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149655
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149667
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149679
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149697
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149709
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149723
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149737
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149751
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149765
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149779
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149793
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149807
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149821
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149835
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149851
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149865
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149879
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149893
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149907
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149921
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149937
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149951
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149965
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149979
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149993
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150007
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150021
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150037
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150051
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150065
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150081
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150093
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150107
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150125
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150139
Principal investigator 1 ModernaTX, Inc. $75.00 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150153
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150169
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150183
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150197
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150211
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150225
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150239
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150253
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150267
Principal investigator 1 ModernaTX, Inc. $158.70 01/30/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041150281
Principal investigator 1 ModernaTX, Inc. $158.70 01/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148111
Principal investigator 1 ModernaTX, Inc. $158.70 01/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148211
Principal investigator 1 ModernaTX, Inc. $158.70 01/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148225
Principal investigator 1 ModernaTX, Inc. $158.70 01/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148357
Principal investigator 1 ModernaTX, Inc. $158.70 01/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148417
Principal investigator 1 ModernaTX, Inc. $158.70 01/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148431
Principal investigator 1 ModernaTX, Inc. $158.70 01/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148673
Principal investigator 1 ModernaTX, Inc. $158.70 01/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148689
Principal investigator 1 ModernaTX, Inc. $158.70 01/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148703
Principal investigator 1 ModernaTX, Inc. $158.70 01/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148717
Principal investigator 1 ModernaTX, Inc. $158.70 01/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148731
Principal investigator 1 ModernaTX, Inc. $158.70 01/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148745
Principal investigator 1 ModernaTX, Inc. $180.00 01/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148759
Principal investigator 1 ModernaTX, Inc. $158.70 01/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148775
Principal investigator 1 ModernaTX, Inc. $158.70 01/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148789
Principal investigator 1 ModernaTX, Inc. $158.70 01/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148805
Principal investigator 1 ModernaTX, Inc. $158.70 01/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148819
Principal investigator 1 ModernaTX, Inc. $158.70 01/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148833
Principal investigator 1 ModernaTX, Inc. $158.70 01/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148847
Principal investigator 1 ModernaTX, Inc. $158.70 01/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148861
Principal investigator 1 ModernaTX, Inc. $158.70 01/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148877
Principal investigator 1 ModernaTX, Inc. $158.70 01/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148891
Principal investigator 1 ModernaTX, Inc. $158.70 01/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148905
Principal investigator 1 ModernaTX, Inc. $158.70 01/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149187
Principal investigator 1 ModernaTX, Inc. $158.70 01/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149439
Principal investigator 1 ModernaTX, Inc. $158.70 01/23/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149453
Principal investigator 1 ModernaTX, Inc. $3,655.62 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041144845
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041144859
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041144873
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041144887
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041144901
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041144915
Principal investigator 1 ModernaTX, Inc. $3,655.62 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041144929
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041144943
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041144959
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041144975
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041144991
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145005
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145019
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145033
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145047
Principal investigator 1 ModernaTX, Inc. $3,655.62 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145061
Principal investigator 1 ModernaTX, Inc. $812.82 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145075
Principal investigator 1 ModernaTX, Inc. $812.82 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145089
Principal investigator 1 ModernaTX, Inc. $3,655.62 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145103
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145117
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145131
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145145
Principal investigator 1 ModernaTX, Inc. $812.82 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145161
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145173
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145187
Principal investigator 1 ModernaTX, Inc. $739.68 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145231
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145245
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145259
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145273
Principal investigator 1 ModernaTX, Inc. $3,655.62 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145287
Principal investigator 1 ModernaTX, Inc. $812.82 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145301
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145315
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145329
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145343
Principal investigator 1 ModernaTX, Inc. $812.82 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145357
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145371
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145385
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145401
Principal investigator 1 ModernaTX, Inc. $3,655.62 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145415
Principal investigator 1 ModernaTX, Inc. $812.82 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145429
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145443
Principal investigator 1 ModernaTX, Inc. $812.82 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145459
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145471
Principal investigator 1 ModernaTX, Inc. $3,655.62 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145487
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145501
Principal investigator 1 ModernaTX, Inc. $3,655.62 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145517
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145531
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145545
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145559
Principal investigator 1 ModernaTX, Inc. $1,078.33 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145573
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145587
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145601
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145615
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145629
Principal investigator 1 ModernaTX, Inc. $2,547.48 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145643
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145657
Principal investigator 1 ModernaTX, Inc. $812.82 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145675
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145685
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145699
Principal investigator 1 ModernaTX, Inc. $3,655.62 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145713
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145727
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145743
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145757
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145771
Principal investigator 1 ModernaTX, Inc. $1,078.33 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145787
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145803
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145815
Principal investigator 1 ModernaTX, Inc. $3,655.62 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145831
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145845
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145859
Principal investigator 1 ModernaTX, Inc. $812.82 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145871
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145887
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145901
Principal investigator 1 ModernaTX, Inc. $3,655.62 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145917
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145931
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145946
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145961
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145973
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041145989
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146001
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146017
Principal investigator 1 ModernaTX, Inc. $812.82 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146031
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146045
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146061
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146071
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146087
Principal investigator 1 ModernaTX, Inc. $812.82 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146101
Principal investigator 1 ModernaTX, Inc. $3,655.62 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146115
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146129
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146143
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146157
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146171
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146185
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146199
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146213
Principal investigator 1 ModernaTX, Inc. $812.82 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146227
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146241
Principal investigator 1 ModernaTX, Inc. $3,655.62 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146255
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146269
Principal investigator 1 ModernaTX, Inc. $812.82 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146283
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146297
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146311
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146325
Principal investigator 1 ModernaTX, Inc. $3,655.62 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146339
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146353
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146367
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146381
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146395
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146409
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146423
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146437
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146451
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146465
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146479
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146493
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146507
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146521
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146535
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146551
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146565
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146577
Principal investigator 1 ModernaTX, Inc. $3,655.62 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146593
Principal investigator 1 ModernaTX, Inc. $3,655.62 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146607
Principal investigator 1 ModernaTX, Inc. $1,956.84 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146621
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146635
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146649
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146663
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146677
Principal investigator 1 ModernaTX, Inc. $3,655.62 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146691
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146705
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146719
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146733
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146749
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146763
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146777
Principal investigator 1 ModernaTX, Inc. $812.82 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146791
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146805
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146819
Principal investigator 1 ModernaTX, Inc. $812.82 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146833
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146845
Principal investigator 1 ModernaTX, Inc. $3,655.62 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146861
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146873
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146891
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146907
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146921
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146935
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146949
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146963
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146977
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041146991
Principal investigator 1 ModernaTX, Inc. $1,956.84 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147005
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147019
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147033
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147047
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147061
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147075
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147089
Principal investigator 1 ModernaTX, Inc. $1,078.33 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147103
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147117
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147135
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147149
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147163
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147177
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147189
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147207
Principal investigator 1 ModernaTX, Inc. $812.82 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147223
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147237
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147251
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147265
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147277
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147293
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147307
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147321
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147335
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147345
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147359
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147373
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147387
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147401
Principal investigator 1 ModernaTX, Inc. $3,655.62 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147415
Principal investigator 1 ModernaTX, Inc. $739.68 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147429
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147443
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147457
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147471
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147487
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147499
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147515
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147529
Principal investigator 1 ModernaTX, Inc. $812.82 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147543
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147557
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147569
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147585
Principal investigator 1 ModernaTX, Inc. $812.82 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147601
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147613
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147627
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147641
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147655
Principal investigator 1 ModernaTX, Inc. $812.82 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147669
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147683
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147697
Principal investigator 1 ModernaTX, Inc. $3,655.62 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147711
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147725
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147739
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147753
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147767
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147781
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147795
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147811
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147825
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147839
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147853
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147867
Principal investigator 1 ModernaTX, Inc. $3,655.62 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147881
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147895
Principal investigator 1 ModernaTX, Inc. $812.82 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147909
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147923
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147937
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147951
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147965
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147979
Principal investigator 1 ModernaTX, Inc. $3,655.62 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041147993
Principal investigator 1 ModernaTX, Inc. $812.82 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148009
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148027
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148041
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148055
Principal investigator 1 ModernaTX, Inc. $3,655.62 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148921
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148935
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148949
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148963
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148977
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041148991
Principal investigator 1 ModernaTX, Inc. $1,956.84 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149005
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149019
Principal investigator 1 ModernaTX, Inc. $812.82 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149033
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149047
Principal investigator 1 ModernaTX, Inc. $3,655.62 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149061
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149075
Principal investigator 1 ModernaTX, Inc. $739.68 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149089
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149103
Principal investigator 1 ModernaTX, Inc. $812.82 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149117
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149131
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149145
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149159
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149173
Principal investigator 1 ModernaTX, Inc. $812.82 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149201
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149215
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149229
Principal investigator 1 ModernaTX, Inc. $666.54 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149243
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149257
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149271
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149285
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149299
Principal investigator 1 ModernaTX, Inc. $3,655.62 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149315
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149331
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149345
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149361
Principal investigator 1 ModernaTX, Inc. $739.68 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149375
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149385
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149399
Principal investigator 1 ModernaTX, Inc. $739.68 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149411
Principal investigator 1 ModernaTX, Inc. $812.82 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149425
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149467
Principal investigator 1 ModernaTX, Inc. $13.80 01/12/2023 Non-covered Recipient Entity
CLINICAL RESEARCH PARTNERS
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041149483
Principal investigator 1 PFIZER INC. $199,925.72 01/12/2023 Non-covered Recipient Entity
Clinical Research Partners LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045895287